India's Biocon reported a huge fiscal year for its CRO arm, growing 36% over the previous year and becoming the largest clinical research provider in the country, the company said.
Icon posted $317 million in revenue last quarter, a 26% jump over the previous year, and the CRO more than doubled its net income.
Quintiles has finally affixed a price tag to its long-held plans to go public, plotting to raise about $790 million and pay down its outstanding debt.
PRA won a $400,000 grant from the Kansas Bioscience Authority, money the CRO will use to create 80 jobs at its Lenexa, KS, facility.
Quintiles pulled in $927 million in revenue last quarter, a 4.2% jump over the same period last year the CRO attributes in part to 2012's many acquisitions.
Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.
India's government is struggling to crack down on loosely regulated clinical trials that have killed hundreds of patients around the country, and while it's unclear if its efforts have made the process safer, they've certainly slowed things down.
Steve Eaton, the former Aptuit employee convicted of manipulating data from hundreds of drug safety studies, has been ordered serve three months in jail, the first such sentencing under the U.K.'s tightened research regulations.
Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.
India's GVK Biosciences has licensed its much-cited database of biological targets, GOSTAR, to the University of Dundee's drug discovery unit.
U.S. preclinical CRO Absorption Systems has signed a deal with Indian consulting firm Synerzys Lifecare, looking to pitch its testing services to the nation's growing generics market.
Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.
As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.
InVentiv Health is betting on a big expansion in Japanese R&D, forming a strategic alliance with local CRO Bell Medical Solutions to offer lab services in the country.
Bristol-Myers Squibb has inked a preferred provider deal with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments.
India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry.
TranScrip Partners is coming to America, as the U.K.-based CRO is opening its first stateside office to expand its global footprint.
Quintiles is planning to dish out a $25 million payment to its founder and controlling shareholders once it goes public, a termination fee designed to make up for the service fees that won't be paid post-IPO.
Global CRO InVentiv Health is shipping out its sample management business to J. Knipper and focusing instead on its other clinical and commercial offerings.
Pharma contracting giant AmerisourceBergen is ditching its commercial packaging business, selling the unit to Frazier Healthcare for $308 million in cash.